Slate Path Capital: Returns, Ethan Binder, Stephen Cook, Jamie McNab

4. Insulet Corporation (NASDAQ:PODD)

Slate Path Capital also disposed of 55,000 shares of Insulet Corporation (NASDAQ:PODD) between April and June, and disclosed a $143.41 million stake containing 2.80 million shares in its latest 13F filing. In this way, Insulet Corporation (NASDAQ:PODD), an insulin delivery system manufacturer, is Slate Path’s largest healthcare holding. Insulet Corporation (NASDAQ:PODD)’s shares have gained nearly 56% since the beginning of the year, amid strong revenue growth, management changes and other developments. In July, the company announced plants to take over the distribution of its Omnipod System in Europe next year after its current distribution contract with a third party expires. Earlier this month, Barclays initiated coverage on Insulet Corporation (NASDAQ:PODD) with an ‘Overweight’ rating and a price target of $65 per share. Despite the strong stock performance, Insulet Corporation (NASDAQ:PODD) has been overlooked by the majority of investors in our database, most likely due to its small size. At the end of June, just 16 funds held shares of the company, up by two over the quarter.